These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1016 related items for PubMed ID: 25132411

  • 21. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 22. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
    Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF.
    J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
    [Abstract] [Full Text] [Related]

  • 23. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R.
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [Abstract] [Full Text] [Related]

  • 24. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Bhat RM, Leelavathy B, Aradhya SS, Gopal MG, Pratap DV, Mubashir M, Srinivas P, Pande SY, Thavkar AS.
    Indian Dermatol Online J; 2017 Oct; 8(1):16-24. PubMed ID: 28217466
    [Abstract] [Full Text] [Related]

  • 25. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J.
    Br J Dermatol; 2024 Aug 14; 191(3):336-343. PubMed ID: 38366639
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
    Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, Baran W.
    J Dermatolog Treat; 2020 Mar 14; 31(2):152-159. PubMed ID: 30887876
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 28. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
    Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, Chaouche-Teyara K.
    J Am Acad Dermatol; 2019 May 25; 80(5):1344-1352. PubMed ID: 30716404
    [Abstract] [Full Text] [Related]

  • 29. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA, Weinberg MA, Morris A, Reich K.
    Lancet; 2021 Apr 24; 397(10284):1564-1575. PubMed ID: 33894834
    [Abstract] [Full Text] [Related]

  • 30. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C.
    J Eur Acad Dermatol Venereol; 2021 Apr 24; 35(4):938-947. PubMed ID: 33068444
    [Abstract] [Full Text] [Related]

  • 31. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
    Sticherling M, Mrowietz U, Augustin M, Thaçi D, Melzer N, Hentschke C, Kneidl J, Sieder C, Reich K.
    Br J Dermatol; 2017 Oct 24; 177(4):1024-1032. PubMed ID: 28580646
    [Abstract] [Full Text] [Related]

  • 32. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P.
    Br J Dermatol; 2012 Jul 24; 167(1):180-90. PubMed ID: 22413944
    [Abstract] [Full Text] [Related]

  • 33. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A.
    Br J Dermatol; 2016 Aug 24; 175(2):273-86. PubMed ID: 26914406
    [Abstract] [Full Text] [Related]

  • 34. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr 24; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 35. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
    Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators.
    Lancet; 2012 Apr 24; 366(9494):1367-74. PubMed ID: 16226614
    [Abstract] [Full Text] [Related]

  • 36. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
    Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L.
    J Dermatolog Treat; 2022 Jun 24; 33(4):2085-2093. PubMed ID: 33947295
    [Abstract] [Full Text] [Related]

  • 37. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
    Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U.
    J Eur Acad Dermatol Venereol; 2018 Sep 24; 32(9):1507-1514. PubMed ID: 29444376
    [Abstract] [Full Text] [Related]

  • 38. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
    Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C, SCULPTURE Study Group.
    J Am Acad Dermatol; 2015 Jul 24; 73(1):27-36.e1. PubMed ID: 25982539
    [Abstract] [Full Text] [Related]

  • 39. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.
    J Am Acad Dermatol; 2018 Aug 24; 79(2):277-286.e10. PubMed ID: 29609013
    [Abstract] [Full Text] [Related]

  • 40. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.
    Lancet; 2017 Jul 15; 390(10091):276-288. PubMed ID: 28596043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.